Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer

por Turina, Claire B, Coleman, Daniel J, Thomas, George V, Fung, Alice W, Alumkal, Joshi J
Publicado 2019

Maintenance and Pharmacologic Targeting of ROR1 Protein Levels via UHRF1 in t(1;19) pre-B-ALL

por Chow, Marilynn, Gao, Lina, MacManiman, Jason D., Bicocca, Vincent T., Chang, Bill H., Alumkal, Joshi J., Tyner, Jeffrey W.
Publicado 2018

Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity

por Monga, Jitender, Adrianto, Indra, Rogers, Craig, Gadgeel, Shirish, Chitale, Dhananjay, Alumkal, Joshi J., Beltran, Himisha, Zoubeidi, Amina, Ghosh, Jagadananda
Publicado 2021

The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity

por Storck, William K., May, Allison M., Westbrook, Thomas C., Duan, Zhi, Morrissey, Colm, Yates, Joel A., Alumkal, Joshi J.
Publicado 2022

Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study

por Cackowski, Frank C., Kumar-Sinha, Chandan, Mehra, Rohit, Wu, Yi-Mi, Robinson, Dan R., Alumkal, Joshi J., Chinnaiyan, Arul M.
Publicado 2020

Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Ade...

por Gao, Bei, Lue, Hui-Wen, Podolak, Jennifer, Fan, Sili, Zhang, Ying, Serawat, Archana, Alumkal, Joshi J., Fiehn, Oliver, Thomas, George V.
Publicado 2019

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

por Graff, Julie N., Alumkal, Joshi J., Drake, Charles G., Thomas, George V., Redmond, William L., Farhad, Mohammad, Cetnar, Jeremy P., Ey, Frederick S., Bergan, Raymond C., Slottke, Rachel, Beer, Tomasz M.
Publicado 2016

Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer

por King, Carly J., Woodward, Josha, Schwartzman, Jacob, Coleman, Daniel J., Lisac, Robert, Wang, Nicholas J., Van Hook, Kathryn, Gao, Lina, Urrutia, Joshua, Dane, Mark A., Heiser, Laura M., Alumkal, Joshi J.
Publicado 2017

Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data

por Sun, Duanchen, Guan, Xiangnan, Moran, Amy E., Wu, Ling-Yun, Qian, David Z., Schedin, Pepper, Dai, Mu-Shui, Danilov, Alexey V., Alumkal, Joshi J., Adey, Andrew C., Spellman, Paul T., Xia, Zheng
Publicado 2022

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer

por Coleman, Daniel J., Gao, Lina, Schwartzman, Jacob, Korkola, James E., Sampson, David, Derrick, Daniel S., Urrutia, Joshua, Balter, Ariel, Burchard, Julja, King, Carly J., Chiotti, Kami E., Heiser, Laura M., Alumkal, Joshi J.
Publicado 2019

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Bioche...

por Aggarwal, Rahul, Alumkal, Joshi J., Szmulewitz, Russell Z., Higano, Celestia S., Bryce, Alan H., Lopez-Gitlitz, Angela, McCarthy, Sharon A., Miladinovic, Branko, McQuarrie, Kelly, Thomas, Shibu, Zhang, Ke, Small, Eric J.
Publicado 2022

Metastatic prostate cancer diagnosed by fine‐needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates

por Cantley, Richard L., Wang, Xiaoming, Reichert, Zachery R., Chinnaiyan, Arul M., Mannan, Rahul, Cao, Xuhong, Spratt, Daniel E., Vaishampayan, Ulka N., Alumkal, Joshi J., Morgan, Todd M., Palapattu, Ganesh, Davenport, Matthew S., Pantanowitz, Liron, Mehra, Rohit
Publicado 2022

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer

por Podolak, Jennifer, Eilers, Kristi, Newby, Timothy, Slottke, Rachel, Tucker, Erin, Olson, Susan B., Lue, Hui-Wen, Youngren, Jack, Aggarwal, Rahul, Small, Eric J., Graff, Julie N., Alumkal, Joshi J., Beer, Tomasz M., Thomas, George V.
Publicado 2017

Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors

por Geybels, Milan S., Alumkal, Joshi J., Luedeke, Manuel, Rinckleb, Antje, Zhao, Shanshan, Shui, Irene M., Bibikova, Marina, Klotzle, Brandy, van den Brandt, Piet A., Ostrander, Elaine A., Fan, Jian-Bing, Feng, Ziding, Maier, Christiane, Stanford, Janet L.
Publicado 2015

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Can...

por Smith, Matthew R., Antonarakis, Emmanuel S., Ryan, Charles J., Berry, William R., Shore, Neal D., Liu, Glenn, Alumkal, Joshi J., Higano, Celestia S., Maneval, Edna Chow, Bandekar, Rajesh, de Boer, Carla J., Yu, Margaret K., Rathkopf, Dana E.
Publicado 2016

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

por Graff, Julie N, Beer, Tomasz M, Alumkal, Joshi J, Slottke, Rachel E, Redmond, William L, Thomas, George V, Thompson, Reid F, Wood, Mary A, Koguchi, Yoshinobu, Chen, Yiyi, Latour, Emile, Bergan, Raymond C, Drake, Charles G, Moran, Amy E
Publicado 2020

Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4

por Coleman, Daniel J., Sampson, David A., Sehrawat, Archana, Kumaraswamy, Anbarasu, Sun, Duanchen, Wang, Yuzhuo, Schwartzman, Jacob, Urrutia, Joshua, Lee, Ahn R., Coleman, Ilsa M., Nelson, Peter S., Dong, Xuesen, Morrissey, Colm, Corey, Eva, Xia, Zheng, Yates, Joel A., Alumkal, Joshi J.
Publicado 2020

Understanding Drug Sensitivity and Tackling Resistance in Cancer

por Tyner, Jeffrey W., Haderk, Franziska, Kumaraswamy, Anbarasu, Baughn, Linda B., Van Ness, Brian, Liu, Song, Marathe, Himangi, Alumkal, Joshi J., Bivona, Trever G., Chan, Keith Syson, Druker, Brian J., Hutson, Alan D., Nelson, Peter S., Sawyers, Charles L., Willey, Christopher D.
Publicado 2022

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

por Coleman, Daniel J., Van Hook, Kathryn, King, Carly J., Schwartzman, Jacob, Lisac, Robert, Urrutia, Joshua, Sehrawat, Archana, Woodward, Josha, Wang, Nicholas J., Gulati, Roman, Thomas, George V., Beer, Tomasz M., Gleave, Martin, Korkola, James E., Gao, Lina, Heiser, Laura M., Alumkal, Joshi J.
Publicado 2016

Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

por Reichert, Zachery R., Kasputis, Tadas, Nallandhighal, Srinivas, Abusamra, Sophia M., Kasputis, Amy, Haruray, Saloni, Wang, Yugang, Williams, Shamara, Singhal, Udit, Alva, Ajjai, Cackowski, Frank C., Caram, Megan E. V., Palmbos, Phillip L., Yentz, Sarah E., Smith, David C., Alumkal, Joshi J., Morgan, Todd M.
Publicado 2021